OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Investigator: Ronald Crystal

3 Projects | 1 Researchers | $4,200,454 Invested

2020

LEXEO Therapeutics, Inc.

Ronald Crystal, MD

Phase I Clinical Trial for the AAV mediated treatment of APOE4 homozygous Alzheimer’s Disease

  • Funding Amount: $1,997,865
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: ApoE, Lipids and Lipoprotein Receptors
  • Status: Active

2017

Weill Medical College of Cornell University

Ronald Crystal, MD

Phase I study of an AAVrh.10-mediated Apolipoprotein E2 Gene Delivery to the CNS for the treatment of Alzheimer's Disease in E4 Homozygotes .

  • Funding Amount: $1,202,589
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: APOE
  • Status: Closed

2014

Weill Medical College of Cornell University

Ronald Crystal, MD

Translation to the Clinic of AAVrh.10-mediated Delivery to the CNS of the Apolipoprotein E2 Gene for Treatment of Alzheimer's Disease

  • Funding Amount: $1,000,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: APOE
  • Status: Closed